1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Diagnostic Medical Systems

Diagnostic Medical Systems

0.90
EUR
+0.01
(+1.13%)
31.81MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.99
3.14
2.6
2.42
1.71
1.51
1.92
1.99
2.25
2.19
2.51
2.25
2.02
- -
Basic EPS, GAAP
-0.13
-0.14
-0.1
-0.07
-0.16
-0.33
-0.19
-0.33
-0.24
-0.42
-0.29
-0.14
-0.01
- -
Free Cash Flow per Basic Share
-0.07
-0.44
-0.47
-0.27
-0.46
-0.25
-0.19
-0.42
-0.43
-0.26
-0.26
- -
-0.1
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.66
1.59
1.59
1.59
1.46
1.12
0.91
1.06
1.16
0.97
0.74
0.64
0.74
0.76
Tangible Book Value per Share
1.18
0.94
0.73
0.77
0.75
0.29
- -
0.19
0.36
0.49
-0.08
-0.29
-0.04
-0.05
Basic Weighted Avg Shares
7
8
14
15
16
16
16
16
16
16
17
20
25
26
Sales/Revenue/Turnover
22
25
36
37
27
24
31
32
36
35
42
46
50
- -
Operating Margin (%)
-4.15
-3.76
-7.88
-4.34
-13.41
-21.36
-9.76
-7.35
-1.35
-14.5
-21.83
-2.87
2.26
- -
Depreciation Expense
1
1
2
1
1
2
1
3
4
3
4
- -
2
- -
Net Income, GAAP
-1
-1
-1
-1
-3
-5
-3
-5
-4
-7
-5
-3
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
60.66
- -
Profit Margin (%)
-4.36
-4.5
-4.04
-2.72
-9.38
-22.2
-10.01
-16.35
-10.68
-19.34
-11.73
-6.25
-0.33
- -
Working Capital
11
19
18
18
14
8
2
6
6
5
10
7
10
13
LT Debt
1
3
3
3
3
3
3
10
10
10
13
12
10
13
Total Equity
13
22
25
28
23
18
15
17
20
18
14
14
21
21
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.26
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.23
- -
Return on Common Equity (%)
-7.13
-6.57
-6.57
-4.14
-10.55
-26.01
-18.98
-32.97
-21.61
-39.66
-35.27
-22.84
-1.04
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
ST Debt
6
9
6
LT Borrowings
8
8
10
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
20
26
Market Capitalization
18
14
32

Working Capital

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
Total Current Assets
30
30
36
Cash, Cash Equivalents & STI
3
6
5
Accounts Receivable, Net
10
7
14
Inventories
15
14
14
Total Current Liabilities
23
23
22
Payables & Accruals
- -
- -
- -
ST Debt
6
9
6
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.23%
6.53%
45.91%
Free Cash Flow
-820.53%
-1,660.1%
-8,166.67%
Net Income, GAAP
14.47%
-22.7%
-94.2%
Sales/Revenue/Turnover
4.37%
9.54%
8.48%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
46
2025
- -
- -
50
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.14
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Samuel Sancerni
Full Time Employees
146
Sector
Health technology
Industry
Medical specialties
Address
9 Avenue du Canal Philippe Lamour Gaillargues-Le-Montueux France 30 660
IPO Date
Jan 1, 1998
Website
dms-imaging.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Diagnostic Medical Systems S.A. (ALDMS.PA) designs, develops, manufactures and sells medical imaging systems focused on digital radiology and bone densitometry for healthcare providers worldwide. The company offers a comprehensive range of products including R/F systems such as Platinum Neo, Baccara dRF 43, EOL and Da Vinci; bone densitometry devices including Stratos dR, Stratos, Challenger Envision and ultrasound imaging system UBIS 5000; mobile x-ray and surgical C-arm solutions; chest and bone room equipment; retrofit kits; mammography systems such as Giotto Image; and innovative software like ADAM. It operates through subsidiaries including AXS Medical, Apelem SAS for radiology equipment, Medilink SARL for Doppler and bone densitometry devices, Apelem SA in Spain and Alpha MOS in France, with presence across all continents via over 140 distributors, subsidiaries and joint ventures. Founded in 1979 and headquartered in Gallargues-le-Montueux, France, the company pursues its Imaging 2027 strategic plan. In August 2025, DMS Group secured a EUR6.9 million capital increase through a strategic alliance with Asian technology providers Innolux and Innocare alongside French investors Bpifrance and NextStage AM to enhance technological capabilities, support industrial expansion by 2030 and strengthen European market leadership in vertically integrated medical imaging. It also advances government-funded projects such as MC2 for mobile x-ray and C-arm development and K for new bone densitometers to improve patient care and personalized medicine.